This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavaldà, J.
Right arrow Articles by Pahissa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavaldà, J.
Right arrow Articles by Pahissa, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2005, p. 3028-3030, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3028-3030.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis

Joan Gavaldà,* María-Teresa Martín, Pedro López, Xavier Gomis, José-Luís Ramírez, Dolors Rodríguez, Oscar Len, Yolanda Puigfel, Isabel Ruíz, and Albert Pahissa

Infectious Diseases Research Laboratory, Infectious Diseases Division, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

Received 21 December 2004/ Returned for modification 21 January 2005/ Accepted 30 March 2005

The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.

* Corresponding author. Mailing address: Servei de Malalties Infeccioses, Hospital General Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain. Phone: 34-93-4894033. Fax: 34-93-2746057. E-mail: jgavalda{at}vhebron.net.

Antimicrobial Agents and Chemotherapy, July 2005, p. 3028-3030, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.3028-3030.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hoeben, B. J., Burgess, D. S., McConville, J. T., Najvar, L. K., Talbert, R. L., Peters, J. I., Wiederhold, N. P., Frei, B. L., Graybill, J. R., Bocanegra, R., Overhoff, K. A., Sinswat, P., Johnston, K. P., Williams, R. O. III (2006). In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 50: 1552-1554 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»